Rhumbline Advisers Has $20.56 Million Stock Holdings in Masimo Co. (NASDAQ:MASI)

Rhumbline Advisers decreased its stake in Masimo Co. (NASDAQ:MASI) by 2.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 124,373 shares of the medical equipment provider’s stock after selling 2,641 shares during the quarter. Rhumbline Advisers’ holdings in Masimo were worth $20,559,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently added to or reduced their stakes in the stock. FMR LLC lifted its stake in Masimo by 41.2% in the third quarter. FMR LLC now owns 6,756,618 shares of the medical equipment provider’s stock valued at $900,860,000 after buying an additional 1,970,883 shares during the period. State Street Corp lifted its stake in Masimo by 0.7% in the third quarter. State Street Corp now owns 1,438,814 shares of the medical equipment provider’s stock valued at $191,837,000 after buying an additional 10,179 shares during the period. Westfield Capital Management Co. LP raised its position in shares of Masimo by 23.2% during the third quarter. Westfield Capital Management Co. LP now owns 1,394,056 shares of the medical equipment provider’s stock worth $185,869,000 after purchasing an additional 262,370 shares during the period. Geode Capital Management LLC raised its position in shares of Masimo by 1.5% during the third quarter. Geode Capital Management LLC now owns 792,886 shares of the medical equipment provider’s stock worth $105,741,000 after purchasing an additional 11,984 shares during the period. Finally, Massachusetts Financial Services Co. MA raised its position in shares of Masimo by 9.8% during the third quarter. Massachusetts Financial Services Co. MA now owns 792,166 shares of the medical equipment provider’s stock worth $105,619,000 after purchasing an additional 70,440 shares during the period. Institutional investors and hedge funds own 85.96% of the company’s stock.

Masimo Stock Down 1.2 %

MASI stock opened at $177.21 on Friday. The company has a quick ratio of 1.11, a current ratio of 2.01 and a debt-to-equity ratio of 0.50. The business has a 50 day moving average price of $172.90 and a two-hundred day moving average price of $151.29. The company has a market cap of $9.49 billion, a price-to-earnings ratio of 122.21 and a beta of 1.02. Masimo Co. has a twelve month low of $101.61 and a twelve month high of $184.51.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the company. Needham & Company LLC reaffirmed a “hold” rating on shares of Masimo in a research report on Wednesday, January 22nd. Raymond James increased their price objective on Masimo from $170.00 to $194.00 and gave the stock an “outperform” rating in a report on Friday, December 27th. Stifel Nicolaus reiterated a “buy” rating and set a $190.00 price objective (up from $170.00) on shares of Masimo in a report on Friday, November 22nd. Wells Fargo & Company increased their price objective on Masimo from $171.00 to $193.00 and gave the stock an “overweight” rating in a report on Wednesday, December 11th. Finally, Piper Sandler increased their price objective on Masimo from $180.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, December 18th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $191.40.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.